# Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer

> **NCT02323906** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 12 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** CC-122
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT02323906
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01-16
- **Primary completion:** 2016-12-21
- **Final completion:** 2016-12-21
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Slow enrollment and business decision. No safety concerns were identified for the study drugs.
- **Last updated:** 2017-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02323906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02323906, "Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02323906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*